Koers BIO-TECHNE Corp Nasdaq
Aandelen
US8783771004
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2024 * | 1,16 mld. 1,07 mld. | Omzet 2025 * | 1,25 mld. 1,15 mld. | Marktkapitalisatie | 13,21 mld. 12,15 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 180 mln. 166 mln. | Nettowinst (verlies) 2025 * | 225 mln. 207 mln. | EV/omzet 2024 * | 11,5 x |
Nettoschuld 2024 * | 178 mln. 164 mln. | Nettoliquiditeiten 2025 * | 16,78 mln. 15,44 mln. | EV/omzet 2025 * | 10,6 x |
K/w-verhouding 2024 * |
75
x | K/w-verhouding 2025 * |
60,1
x | Werknemers | - |
Dividendrendement 2024 * |
0,38% | Dividendrendement 2025 * |
0,38% | Vrij verhandelbaar | 99,03% |
Recentste transcriptie over BIO-TECHNE Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Kim Kelderman
CEO | Chief Executive Officer | 57 | 30-04-18 |
James Hippel
DFI | Director of Finance/CFO | 53 | 01-04-14 |
Matthew McManus
COO | Chief Operating Officer | 55 | 08/01 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 68 | 01-01-03 | |
Randolph Steer
BRD | Director/Board Member | 74 | 01-01-90 |
Joseph Keegan
BRD | Director/Board Member | 71 | 26-10-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,09% | 42,12 mld. | |
+49,62% | 42,05 mld. | |
-4,96% | 29,18 mld. | |
+11,18% | 26,02 mld. | |
-21,95% | 18,9 mld. | |
+24,73% | 12,17 mld. | |
+28,31% | 12,16 mld. | |
-6,26% | 11,42 mld. | |
+2,05% | 10,14 mld. |
- Beurs
- Aandelen
- Koers TECH
- Koers